XHANCE significantly reduced both symptoms and sinus opacification in participants with chronic sinusitis in two randomized controlled Phase 3 Clinical Trials FDA Supplemental New Drug Application.
International leaders in otolaryngology to provide guidance in development and strategic growth for intranasal drug delivery technologiesPLATTSBURGH, N.Y., Oct. 28, 2021 NasoNeb, Inc. , a.